|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.41 - 31.54|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.63|
|Dividend & Yield||1.03 (3.26%)|
|1y Target Est||N/A|
Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Roche Holding AG Here are 5 ETFs with the largest exposure to RHHBY-US. Comparing the performance and risk of Roche Holding AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Drugmakers’ shares often react strongly to initial reports on a new treatment’s effectiveness—only to dramatically reverse course when the full study is later released.